Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study

Scientific Reports

Volumn 7, Issue , 2017, Pages

  De Mello, Vanessa D ^a   Paananen, Jussi ^a   Lindström, Jaana ^b   Lankinen, Maria A ^a   Shi, Lin ^c   Kuusisto, Johanna ^d   Pihlajamäki, Jussi ^a,d   Auriola, Seppo ^a,e   Lehtonen, Marko ^a,e   Rolandsson, Olov ^f   Bergdahl, Ingvar A ^f   Nordin, Elise ^c   Ilanne Parikka, Pirjo ^g,h   Keinänen Kiukaanniemi, Sirkka ^i,j   Landberg, Rikard ^c,k   Eriksson, Johan G ^b,l,m,n,o   Tuomilehto, Jaakko ^b,p,q   Hanhineva, Kati ^a,e   Uusitupa, Matti ^a,d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e LC MS Metabolomics Center   (Finland)

^f UMEÅ UNIVERSITY   (Sweden)

^g Finnish Diabetes Association   (Finland)

^h TAMPERE UNIVERSITY HOSPITAL   (Finland)

ⁱ UNIVERSITY OF OULU   (Finland)

^j OULU UNIVERSITY HOSPITAL   (Finland)

^k KAROLINSKA INSTITUTE   (Sweden)

^l UNIVERSITY OF HELSINKI   (Finland)

^m FOLKHÄLSAN RESEARCH CENTER   (Finland)

ⁿ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^o VAASA CENTRAL HOSPITAL   (Finland)

^p DANUBE UNIVERSITY KREMS   (Austria)

^q KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BILE ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INDOLE DERIVATIVE; INDOLEPROPIONIC ACID; INSULIN; LIPID;

AGED; DIETARY FIBER; FEMALE; FINLAND; HEALTH SURVEY; HUMAN; LIFESTYLE; LIPID METABOLISM; MALE; METABOLISM; METABOLOMICS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SECRETION (PROCESS);

AGED; AMINO ACIDS; BILE ACIDS AND SALTS; BIOMARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIETARY FIBER; FEMALE; FINLAND; HUMANS; INDOLES; INSULIN; LIFE STYLE; LIPID METABOLISM; LIPIDS; MALE; METABOLOMICS; MIDDLE AGED; POPULATION SURVEILLANCE; RISK ASSESSMENT; RISK FACTORS;

EID: 85017387045     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep46337     Document Type: Article

References (54)

1. Wang, T. J., et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17, 448-453 (2011).
2. Floegel, A., et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 62, 639-648 (2013).
3. Menni, C., et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 62, 4270-4276 (2013).
4. Meikle, P. J., et al. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS One 8, e74341 (2013).
5. Hanhineva, K., et al. Nontargeted metabolite profiling discriminates diet-specific biomarkers for consumption of whole grains, fatty fish, and bilberries in a randomized controlled trial. J. Nutr. 145, 7-17 (2015).
6. Lindström, J., et al. Improved lifestyle and decreased diabetes risk over 13 years: Long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia 56, 284-293 (2013).
7. de Mello, V. D., et al. Insulin secretion and its determinants in the progression of impaired glucose tolerance to type 2 diabetes in impaired glucose-tolerant individuals: The Finnish Diabetes Prevention Study. Diabetes Care 35, 211-217 (2012).
8. Lankinen, M. A., et al. Plasma fatty acids as predictors of glycaemia and type 2 diabetes. Diabetologia 58, 2533-2544 (2015).
9. Rolandsson, O., et al. How to diagnose and classify diabetes in primary health care: Lessons learned from the Diabetes Register in Northern Sweden (DiabNorth). Scand. J. Prim. Health Care 30, 81-87 (2012).
10. Smith, E. A., Macfarlane, G. T. Enumeration of human colonic bacteria producing phenolic and indolic compounds: Effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. J. Appl. Bacteriol. 81, 288-302 (1996).
11. Smith, E. A., Macfarlane, G. T. Formation of Phenolic and Indolic Compounds by Anaerobic Bacteria in the Human Large Intestine. Microb. Ecol. 33, 180-188 (1997).
12. Wikoff, W. R., et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA 106, 3698-3703 (2009).
13. Haeusler, R. A., Astiarraga, B., Camastra, S., Accili, D., Ferrannini, E. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes 62, 4184-4191 (2013).
14. Guasch-Ferré, M., et al. Dietary fat intake and risk of cardiovascular disease and all-cause mortality in a population at high risk of cardiovascular disease. The American Journal of Clinical Nutrition (2015).
15. Chimerel, C., et al. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell. Rep. 9, 1202-1208 (2014).
16. Garber, A. J. Incretin effects on beta-cell function, replication, and mass: The human perspective. Diabetes Care 34 Suppl 2, S258-63 (2011).
17. Chyan, Y. J., et al. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J. Biol. Chem. 274, 21937-21942 (1999).
18. Karbownik, M., et al. Indole-3-propionic acid, a melatonin-related molecule, protects hepatic microsomal membranes from ironinduced oxidative damage: Relevance to cancer reduction. J. Cell. Biochem. 81, 507-513 (2001).
19. Halban, P. A., et al. Beta-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment. Diabetes Care 37, 1751-1758 (2014).
20. Lutz, T. A., Meyer, U. Amylin at the interface between metabolic and neurodegenerative disorders. Front. Neurosci. 9, 216 (2015).
21. Haro, C., et al. Two healthy diets modulate gut microbial community improving insulin sensitivity in a human obese population. J. Clin. Endocrinol. Metab. 101, 233-242 (2016).
22. Marchesi, J. R., et al. The gut microbiota and host health: A new clinical frontier. Gut 65, 330-339 (2016).
23. De Filippis, . F., et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut (2015).
24. Landberg, R., Aman, P., Hallmans, G., Johansson, I. Long-term reproducibility of plasma alkylresorcinols as biomarkers of wholegrain wheat and rye intake within Northern Sweden Health and Disease Study Cohort. Eur. J. Clin. Nutr. 67, 259-263 (2013).
25. InterAct Consortium. Dietary fibre and incidence of type 2 diabetes in eight European countries: The EPIC-InterAct Study and a meta-analysis of prospective studies. Diabetologia 58, 1394-1408 (2015).
26. Qin, J., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60 (2012).
27. Soga, T., et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun. 326, 744-751 (2005).
28. Yea, K., et al. Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes. J. Biol. Chem. 284, 33833-33840 (2009).
29. Pedersen, H. K., et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535, 376-381 (2016).
30. Wang, X., et al. Inflammatory markers and risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes Care 36, 166-175 (2013).
31. Liu, C., et al. Adiponectin, TNF-alpha and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine 86, 100-109 (2016).
32. Pfeuffer, M., Jaudszus, A. Pentadecanoic and Heptadecanoic Acids: Multifaceted Odd-Chain Fatty Acids. Adv. Nutr. 7, 730-734 (2016).
33. Jenkins, B. ., West, J. A., Koulman, A. A review of odd-chain fatty acid metabolism and the role of pentadecanoic Acid (c15:0) and heptadecanoic Acid (c17:0) in health and disease. Molecules 20, 2425-2444 (2015).
34. Lahti, L., et al. Associations between the human intestinal microbiota, Lactobacillus rhamnosus GG and serum lipids indicated by integrated analysis of high-throughput profiling data. PeerJ 1, e32 (2013).
35. Fu, J., et al. The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids. Circ. Res. 117, 817-824 (2015).
36. Wang-Sattler, R., et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol. Syst. Biol. 8, 615 (2012).
37. Walford, G. A., et al. Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes. Diabetes Care 37, 2508-2514 (2014).
38. Wittenbecher, C., et al. Amino acids, lipid metabolites, and ferritin as potential mediators linking red meat consumption to type 2 diabetes. Am. J. Clin. Nutr. 101, 1241-1250 (2015).
39. Wurtz, P., et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care 35, 1749-1756 (2012).
40. Wurtz, P., et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care 36, 648-655 (2013).
41. Xu, F., et al. Metabolic signature shift in type 2 diabetes mellitus revealed by mass spectrometry-based metabolomics. J. Clin. Endocrinol. Metab. 98, E1060-5 (2013).
42. Sonne, D. P., Hansen, M., Knop, F. K. Bile acid sequestrants in type 2 diabetes: Potential effects on GLP1 secretion. Eur. J. Endocrinol. 171, R47-65 (2014).
43. Hansen, M., Sonne, D. P., Knop, F. K. Bile acid sequestrants: Glucose-lowering mechanisms and efficacy in type 2 diabetes. Curr. Diab Rep. 14, 482014-04824 (2014).
44. Flynn, C. R., et al. Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. Nat. Commun. 6, 7715 (2015).
45. Ridlon, J. M., Kang, D. J., Hylemon, P. B., Bajaj, J. S. Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 30, 332-338 (2014).
46. Venkatesh, M., et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity 41, 296-310 (2014).
47. Cani, P. D., Osto, M., Geurts, L., Everard, A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 3, 279-288 (2012).
48. Tuomilehto, J., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343-1350 (2001).
49. Wierzbicka, R., Wu, H., Franek, M., Kamal-Eldin, A., Landberg, R. Determination of alkylresorcinols and their metabolites in biological samples by gas chromatography-mass spectrometry. J. Chromatogr. B. Analyt Technol. Biomed. Life. Sci. 1000, 120-129 (2015).
50. Stancáková, A., et al. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6, 414 Finnish men. Diabetes 58, 1212-1221 (2009).
51. de Mello, V. D., et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutr. Metab. Cardiovasc. Dis. 25, 635-642 (2015).
52. Smith, C. A., Want, E. J., O'Maille, G., Abagyan, R., Siuzdak, G. XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78, 779-787 (2006).
53. Brunius, C., Shi, L., Landberg, R. Large-scale untargeted LC-MS metabolomics data correction using between-batch feature alignment and cluster-based within-batch signal intensity drift correction. Metabolomics 12, 173 (2016).
54. Willett, W. C. In Monographs in Epidemiology and Biostatistics; Nutritional Epidemiology (eds Kelsey, J. L., Marmot, M. C., Stolley, P. D., Vessey, M. P. ) 1-514 (Oxford University PressWillett, W. C, Oxford, 1998).